CRISPR Therapeutics AG CRSP
54.23
(1.47)
(2.64%)
as of 25 Sep
- Market cap
- $5.4B
- P/E
- 0.0×
Follow CRSP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (26.09%) | (31.21%) | (30.18%) | (25.33%) |
+8 more TTM periods Free account |
|
| (19.28%) | (23.24%) | (25.81%) | (21.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (131,984.38%) | |
Return on Tangible Assets |
(19.22%) | (23.45%) | (29.79%) | (25.29%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.85) | (4.18) | (3.85) | (3.32) | |
Free Cash Flow |
(371.32) | (401.18) | (345.93) | (303.14) | |
Capital Expenditures |
(1.74) | (1.21) | (0.91) | (0.65) | |
Piotroski F-Score |
3.00 | 2.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(7.87%) | (8.26%) | (8.85%) | (7.89%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
2,095.48% | 9,192.03% | 10,856.38% | 963.23% | |
Selling, General and Administrative Expense of Revenue |
523.19% | 1,740.90% | 2,095.21% | 191.11% | |
Share Based Compensation of Revenue |
510.16% | 1,672.22% | 2,065.50% | 199.21% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 0.70 | 0.59 | 0.62 | |
Depreciation/Fixed assets |
0.17 | 0.17 | 0.17 | 0.15 | |
Capex/Depreciation |
(0.09) | (0.06) | (0.05) | (0.03) | |
Revenue per Share |
0.14 | 0.04 | 0.04 | 0.42 | |
Operating CF per Share |
(3.83) | (4.16) | (3.84) | (3.31) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.13 | 0.30 | 0.26 | 0.02 | |
Net Profit Margin |
(3,368.72%) | (13,856.54%) | (16,569.77%) | (1,273.70%) |
Columns are period end dates